US Bancorp’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.1K | Sell |
754
-18
| -2% | -$581 | ﹤0.01% | 3059 |
|
|
2026
Q1 | $24.5K | Buy |
772
+50
| +7% | +$1.36K | ﹤0.01% | 3017 |
|
|
2025
Q4 | $19.6K | Hold |
722
| – | – | ﹤0.01% | 3089 |
|
|
2025
Q3 | $18.7K | Sell |
722
-15
| -2% | -$348 | ﹤0.01% | 3097 |
|
|
2025
Q2 | $15K | Buy |
737
+485
| +192% | +$9.44K | ﹤0.01% | 3285 |
|
|
2025
Q1 | $4.57K | Sell |
252
-257
| -50% | -$5.74K | ﹤0.01% | 3688 |
|
|
2024
Q4 | $12.9K | Sell |
509
-173
| -25% | -$4.7K | ﹤0.01% | 3324 |
|
|
2024
Q3 | $23.2K | Buy |
682
+45
| +7% | +$1.72K | ﹤0.01% | 3070 |
|
|
2024
Q2 | $23.6K | Sell |
637
-33
| -5% | -$1.25K | ﹤0.01% | 2997 |
|
|
2024
Q1 | $28.1K | Buy |
670
+71
| +12% | +$2.92K | ﹤0.01% | 2952 |
|
|
2023
Q4 | $23.8K | Buy |
599
+480
| +403% | +$14.1K | ﹤0.01% | 2977 |
|
|
2023
Q3 | $3.27K | Sell |
119
-230
| -66% | -$7.21K | ﹤0.01% | 3556 |
|
|
2023
Q2 | $11.8K | Sell |
349
-57
| -14% | -$1.92K | ﹤0.01% | 3203 |
|
|
2023
Q1 | $14.6K | Hold |
406
| – | – | ﹤0.01% | 3139 |
|
|
2022
Q4 | $18.1K | Hold |
406
| – | – | ﹤0.01% | 3043 |
|
|
2022
Q3 | $11K | Hold |
406
| – | – | ﹤0.01% | 3331 |
|
|
2022
Q2 | $11K | Hold |
406
| – | – | ﹤0.01% | 3330 |
|
|
2022
Q1 | $14K | Hold |
406
| – | – | ﹤0.01% | 3241 |
|
|
2021
Q4 | $16K | Hold |
406
| – | – | ﹤0.01% | 3226 |
|
|
2021
Q3 | $22K | Hold |
406
| – | – | ﹤0.01% | 3076 |
|
|
2021
Q2 | $14K | Hold |
406
| – | – | ﹤0.01% | 3283 |
|
|
2021
Q1 | $8K | Buy |
406
+50
| +14% | +$1.15K | ﹤0.01% | 3357 |
|
|
2020
Q4 | $6K | Buy |
+356
| New | +$6.41K | ﹤0.01% | 3337 |
|
|
2020
Q3 | – | Sell |
-6
| Closed | – | – | 3722 |
|
|
2020
Q2 | $0 | Buy |
+6
| New | +$27 | ﹤0.01% | 3734 |
|
|
2017
Q3 | – | Sell |
-25
| Closed | -$1K | – | 3579 |
|
|
2017
Q2 | $1K | Hold |
25
| – | – | ﹤0.01% | 3447 |
|
|
2017
Q1 | $1K | Buy |
+25
| New | +$1.3K | ﹤0.01% | 3451 |
|
|
2016
Q1 | – | Sell |
-127
| Closed | -$30K | – | 3538 |
|
|
2015
Q4 | $30K | Buy |
127
+106
| +505% | +$23.1K | ﹤0.01% | 2655 |
|
|
2015
Q3 | $3K | Hold |
21
| – | – | ﹤0.01% | 3342 |
|
|
2015
Q2 | $8K | Sell |
21
-221
| -91% | -$87.8K | ﹤0.01% | 3185 |
|
|
2015
Q1 | $102K | Sell |
242
-282
| -54% | -$101K | ﹤0.01% | 2152 |
|
|
2014
Q4 | $144K | Sell |
524
-119
| -19% | -$29.6K | ﹤0.01% | 1928 |
|
|
2014
Q3 | $125K | Buy |
643
+78
| +14% | +$17K | ﹤0.01% | 1992 |
|
|
2014
Q2 | $138K | Sell |
565
-1,423
| -72% | -$321K | ﹤0.01% | 1967 |
|
|
2014
Q1 | $527K | Sell |
1,988
-177
| -8% | -$67.8K | ﹤0.01% | 1304 |
|
|
2013
Q4 | $787K | Buy |
2,165
+1,287
| +147% | +$496K | ﹤0.01% | 1048 |
|
|
2013
Q3 | $467K | Buy |
878
+197
| +29% | +$67.5K | ﹤0.01% | 1277 |
|
|
2013
Q2 | $160K | Buy |
+681
| New | +$134K | ﹤0.01% | 1758 |
|
Other funds holding CLDX
KCM
DTC
LGM
US Bancorp's CLDX Position: Q2 2026 in Review
US Bancorp reduced its Celldex Therapeutics (CLDX) stake by 2.3% in Q2 2026, selling an estimated $581 and leaving 754 shares worth $28.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3059.
US Bancorp first reported a position in CLDX in Q2 2013 and has held it in 37 quarters since. The position peaked at $787K in Q4 2013. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.
- US Bancorp held 754 shares of Celldex Therapeutics worth $28.1K as of Q2 2026.
- US Bancorp sold 18 Celldex Therapeutics shares in Q2 2026, an estimated $581.
- Celldex Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3059 holding.
- US Bancorp first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 37 quarters since.
- US Bancorp's Celldex Therapeutics position peaked at $787K in Q4 2013.
- 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.